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ABSTRACT




University of New Hampshire, December 2006 
Bacterial sepsis and systemic inflammatory immune responses continue to be 
major causes of illness and death despite extensive research into the development of 
antimicrobial agents. There is a need for novel therapeutic reagents designed to modulate 
these responses. Toll-like receptor 2 plays a key role in the development of innate and 
adaptive immune responses to microbial products that interact with the receptor’s 
extracellular leucine-rich repeat ligand-binding domain. In a preliminary study, five 
peptides were synthesized that bound to the leucine-rich repeat region of Toll-like 
receptor 2 (TLR2). We tested the hypothesis that the novel TLR 2 leucine rich repeat 
binding peptides affects TLR2-mediated immune function by examining the ability of 
the five peptides to induce the maturation of bone marrow derived-dendritic cells in vitro. 
The dendritic cells were cultured in the presence of the peptides and maturation was 
determined through flow cytometry and cytokine analysis. We discovered that dendritic 
cells produced interleukin-6 to the JT1 leucine-rich repeat binding peptide. Some 
activation of the MHC class II dendritic cell maturation marker was observed in response 
to peptide JT1. Our results indicate that the JT1 synthetic toll-like receptor 2 leucine rich 
repeat binding peptide induces maturation of bone marrow derived dendritic cells in 
vitro.
viii
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CHAPTER I
INTRODUCTION
AH healthy human beings possess both innate and adaptive immunity. The innate 
immune system is the first defense against invading microbial pathogens and elicits a 
generalized response through recognition of specific molecular patterns by effector cells. 
The innate response is invariant however frequently exposure to the microbe occurs. 
Innate immunity is essential for timely detection and containment of an infection 
(Aderem and Smith, 2004).
Adaptive immunity prevents pathogen re-infection and often includes antibody 
production. This response usually occurs no later than 96 hours after the start of infection 
(Janeway 2005). Though the adaptive response is more complex than the innate response, 
the two are strongly interrelated. Adaptive immunity involves clonal selection of a 
repertoire of T and B-lymphocytes from an extremely diverse pool of cells bearing 
antigen-specific receptors that mediate pathogen binding. In response to activation, T- 
cells bearing receptors that bind to the cognate antigen undergo clonal selection; they also 
up-regulate cell surface molecules that are co-stimulatory to B cells, including B7 and 
CD40c. Antigen-specific lymphocytes proliferate and differentiate into effector cells 
leading to pathogen destruction via a variety of mechanisms that include direct killing by 
cytotoxic T-cells and phagocytosis (Janeway 2005, Paul, 1993). Clonal selection also 
results in the production of differentiated memory lymphocytes, allowing a more rapid 
and specific response in recurrent infections.
1
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(Figure adapted from Takeda and Akira, 2001)
Dendritic cell maturation occurs upon TLR-mediated pathogen recognition and 
phagoctyosis. TLR activation leads to the production of co stimulatory molecules as well 
as inflammatory cytokines that assist in antigen presentation to naive T cells and with T 
cell maturation to Thl cells.
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The Role of Innate Immunity
Antigen-presenting cells (APCs), such as dendritic cells and macrophages, are key 
effector cells of the innate immune response. These cells recognize pathogens via a 
family of extracellular receptors known as Toll-like receptors (TLRs) (Aderem and 
Smith, 2004, Satthapom and Eremin, 2001). Toll-like receptor activation causes the 
phagocytosis and subsequent degradation of a pathogen via proteolytic cleavage. 
Intracellular processing results in the presentation of antigenic peptides on the cellular 
surface within the context of the class I major histocompatiblity complex proteins 
(MHC). Dendritic cells (DCs) possess the ability to stimulate naive T cells (Satthapom 
and Eremin, 2001), upregulating the production of inflammatory cytokines such as 
interleukins 6, 8,10 (IL 6, 8,10) and interferon gamma (IFN-y). The inflammatory 
response results in blood vessel dilation and phagocyte migration, localizing the pathogen 
and inhibiting the further spread of infection.
The inflammatory response can result in serious negative consequences such as 
the release of reactive oxidizing compounds and lysosomal contents by effector cells 
resulting in tissue damage and necrosis. Systemic bacterial infections result in a 
widespread inflammatory response called sepsis. The consequences are high fever, 
hypotension, severe tissue destruction, respiratory distress, shock, organ failure, and 
eventual death (Janeway, 2005). The innate immune response has a critical role in the 
maintenance of human health. Therefore the ability to modulate or control this response 
could save thousands of lives (Martin, 2003), or significantly improve the quality of life 
for millions.
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Toll-Like Receptors
An inflammatory response is the result of phagocyte activation through 
recognition of pathogen-associated molecular patterns (PAMPs), which are microbe- 
associated lipoproteins, or of other cell wall components such as lipopolysaccharides and 
peptidoglycan. Recognition occurs through a family of receptors on the surface of 
leukocytes known as TLRs. TLRs are transmembrane proteins containing an 
extracellular region consisting of a leucine-rich repeat domain (LRR) that mediates 
binding to the PAMP. There are eleven human TLRs currently known. Each is thought 
to recognize a specific PAMP associated with a wide variety of pathogens. Toll-like 
receptor 4 (TLR4) produces an immune response when activated by lypopolysaccharide 
(LPS), a major constituent of gram-negative bacteria cell walls. Toll-like receptor 5 
(TLR5) recognizes flagellin protein; CpG DNA activates Toll-like receptor 9 (TLR9) and 
peptidoglycan activates TLR2 (reviewed in Takeda and Akira, 2001). A single pathogen 
can activate several different TLRs via its associated PAMPs. The activation of each 
TLR brings about both an individual specific response, such as the production of tumor 
necrosis factor a  (TNF-a) by TLR2 and more generally the activation of NF-kB. Toll­
like receptors have an intracellular carboxy-terminus that contains a highly conserved 
region called the Toll/interleukin-1 receptor (TIR) homology domain. Toll-like receptor 
activation and subsequent pathway stem from heterodimerization of the TIR domain and 
the MyD88 adaptor protein’s domain (figure 2). This results in the recruitment and 
phosphorylation of the interleukin -1 (IL-1) receptor associated kinase (IRAK) a 
serine/threonine kinase whose death domain interacts with the death domain of MyD88. 
IRAK associates with the TNF receptor-associated factor 6 (TRAF6) adaptor protein,
4
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Figure 2. The Toll-like Receptor MyD88-dependent Signaling Pathway
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5
activating the TGF activated kinase and mitogen-activated protein (MAP) kinase kinase 
(MKK6) which activates NF-kB, c-Jun N-terminal kinase (JNK) and AP-1 and the p38 
MAP kinase signaling pathways (reviewed in Armant and Fenton, 2002). This results in 
the production of pro-inflammatory cytokine production such as interleukins, TNF-alpha 
and of inducible nitrogen oxide synthesis (NOS-2) (Hallman et al., 2001).
The recognition of microbial PAMPs by TLRs may occur via interactions of a 
monomeric TLR with its ligand or via the homodimerization of the TLRs, as is seen with 
TLR2. Ligand recognition may also occur through cooperative binding between 
different TLRs forming heterodimers. This cooperative binding allows a greater 
repertoire of PAMPs to be recognized (Ozinsky, 2000). Both TLR2 and TLR6 have been 
shown to work cooperatively to bring about phagocyte activation through exposure to 
peptidoglycan, phenol soluble modulin (PSM), Outer surface A lipoprotein (Osp-L), and 
Soluble Tuberculosis Factor (STF) (Bulut, 2001).
The PAMPs recognized by TLR2 may explain how a variety of pathogens can 
interact with a single receptor, but does not explain the complex repertoire of TLR2 
responses to pathogen-derived molecules, such as the activation of transcription factors, 
pro-inflammatory responses, MyD88-dependent and independent pathways, as well as 
modulation of Thl and Th2 responses. How TLR-mediated immune responses are 
specifically tailored to particular pathogens is a key question that needs to be answered. 
One explanation is that TLRs can discriminate between complex molecular signatures 
that characterize specific pathogen subsets, and that the specificity of this subset is 
translated into an appropriate immune response. We have begun to explore this model by
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
asking what specifically at the molecular level, is the repertoire of residues or epitopes 
recognized by the TLR2-LRR.
Leucine Rich Repeat Proteins
TLRs are members of a growing super family of Leucine Rich Repeat (LRR) 
proteins that participate in reversible high-affinity interactions with other peptides. 
Leucine Rich Repeat proteins have been implicated in complex cellular processes such as 
hormone binding and cell adhesion, as well as signal transduction pathways (Kajava, 
1998). The LRR domains of these proteins are highly conserved and a typical motif is 
characterized by 5-17 tandem arrays of a leucine-rich consensus sequence containing 20- 
29 leucine residues. A single repeat is typically characterized by the sequence 
LxxLxxLxLxxNxLxxLpxxoFxx, where x is any residue, p is any polar residue, and o is 
any nonpolar residue. This sequence represents an N-terminal beta-strand, an asparagine 
tum-region, and a C-terminal alpha helix (Kobe and Deisenhofer, 1994; Kajava, 1998).
The porcine ribonuclease inhibitor is a protein (Figure 3) consisting entirely of 
LRRs. The crystal structure of this protein indicates that each LRR is a modular unit, 
made up of a beta strand, an asparagine turn region, and an alpha helix. Tandem repeats 
are parallely aligned on a mutual axis (Kobe and Deisnhofer, 1994; Kajava 1998) 
resulting in a horseshoe shaped molecule consisting of parallel beta sheets along the inner 
portion of the domain, with the helices flanking the outer surface (Kobe and Deisenhofer, 
1994). Ligand binding to the LRR is mediated by the interstitial non-consensus residues, 
occurring as areas on either surface of the LRR. The expansive solvent-exposed inner 
and outer surfaces may accommodate the simultaneous binding of multiple ligands. The
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
Figure 3. X-ray Crystallographic Structure of Porcine Ribonuclease 
Inhibitor Protein.
Figure adapted from Chen and Shapiro, 1997
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conserved leucines within the LRRs are structural and not involved in ligand recognition. 
(Kajava, 1998, Clark et al.).
The yeast CCR4 deadenylase protein contains one partial and five complete LRRs 
(Malvar et al., 1992). A study determined that the LRR of CCR4 binds to its own 
deadenylase domain and deletion of this LRR resulted in the loss of CCR4’s enzymatic 
function. Mutations in the beta-sheet surface of the CCR4-LRR resulted in a significant 
reduction in the proteins enzymatic activity (Clark et al., 2004, Meng et al. 2003). A 
small number of residues modulate ligand binding to CCR4-LRR, with multiple ligands 
able to bind simultaneously to the surface of a single LRR (Clark et al., 2004).
Toll-Like Receptor 2
TLR2 is expressed on monocytes, peripheral blood lymphocytes, 
polymorphonuclear leukocytes, and dendritic cells (reviewed in Hallman et al., 2001) and 
recognizes ligands from a wide variety of bacterial, fungal, and viral components. The 
repertoire of known TLR2 ligands is expanding, but it is not known if these ligands 
contain a common motif. Toll-like receptor 2 contains approximately 19 LRRs within its 
extracellular domain (Kirschning and Schumann, 2002) that are responsible for ligand 
recognition (Iwaki et al., Meng et al., 2004). The TLR2-LRR domain interacts with 
Staphylococcus aureus peptidoglycan, as well as various lipoproteins (Fujita et al., 2003; 
Mitsuzawa et al., 2001). It is not known if the TLR2-LRR alone is responsible for all 
interactions between TLR2 and its respective ligands.
The utility of developing new TLR2 directed agonist/antagonists is that human 
autoimmune diseases and antibiotic-resistant bacterial infections are on the rise, and a 
critical need exists to characterize receptor-ligand interactions that play key roles in
9
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human health and develop novel therapeutic reagents designed to modulate these 
interactions. Expanded knowledge of specific peptide sequences recognized by the 
TLR2-LRR could reveal the existence of a common binding motif among PAMPs. Such 
motifs could represent novel targets for development of therapeutic molecules.
Phenol soluble modulin (PSM) is a known TLR2 ligand and is produced by 
Staphylococcus epidermidis (Hajjar, 2001) and other staphylococci species which have 
been implicated in catheter related sepsis. The development of a TLR2 antagonist could 
prevent PSM from initiating an inflammatory response, lessening the likelihood of sepsis.
Mycobacterium tuberculosis is a TLR2 agonist and the most common of the 
tuberculosis-causing pathogens. Tuberculosis affects more than 60 million individuals 
world wide, and kills approximately 10 million annually (Janeway, 2005). M. 
tuberculosis produces soluble tuberculosis factor (STF), a known TLR2 antagonist 
(Bulut, 2001). This bacterium is an intracellular pathogen that evades innate immune 
responses (Paul, 1993). Modulation of TLR2 via competitive inhibition by small 
therapeutic peptides could allow individuals to mount a more effective immune response 
against this pathogen. While this may not be a complete cure for the disease, peptide- 
based therapeutics could expand treatment options.
Atherosclerosis is another human disease in which TLR2 involvement contributes 
to pathology. Peptidoglycan (PG), a known TLR2 agonist, has been discovered in 
atherosclerotic plaques. One study found that arterial TLR2 when activated by the 
peptidoglycan found in the plaques contributed to plaque formation (Schoneveld et al., 
2005). Therapeutically regulating TLR2 activation by PG could serve to prevent
10
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atherosclerosis.
Preliminary Studies
In a preliminary study, a yeast two-hybrid system was used to identify the specific 
ligand residues that mediate binding to the CCR4-LRR. Twenty-one unique peptides 
from a random peptide aptamer library of 2x109 possible clones were isolated based on 
their ability to bind to the CCR4-LRR. Through sequencing, a highly conserved 
consensus sequence consisting of [G/P]-(3)[L/V/I/F] was found in the majority of the 
peptides (Lisa Clark, personal communication). The findings suggested that a motif 
consisting of four residues could play a key role in the interactions of the peptide 
aptamers with the CCR4-LRR peptide-binding surface.
Based upon these results, a study was undertaken to determine whether a similar 
conserved motif could be found among TLR2-LRR-peptide ligands. A FliTrx ™ random 
peptide display library (Figure 4) was used as a tool to discover peptides that physically 
bind to the TR2-LRR. The FliTrx™ system contains approximately lx l08 unique clones 
and functions by displaying random 12-mer peptides on the surface of E.coli flagella.
The peptides are inserted into the active loop of the thioredoxin scaffold protein. The 
thioredoxin A peptide fusions are contained within the dispensable region of the major 
bacterial flagellar gene (FliTrx™) (Figure 4). Working with this peptide library led to 
the discovery of 17 peptides that bound to the TLR2-LRR. Sequence analysis showed 
that 11 of the 17 peptides contained a common motif of [Gxx(V/L/I)j (Tierney, 2005 
Master’s thesis). Five of these eleven peptides were designated JT1-JT5, synthesized, 
and used in cellular activation assays to determine whether they were biologically active 
(Table 1).
11
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Peptide Therapeutics
The development of novel peptide-based therapeutics has been under intensive 
investigation in recent years. Peptide based drugs contain fewer than 100 amino acids 
(Wieland, 1995) and are easily degraded and rapidly removed from the circulation by the 
kidneys. The short life of these peptides can be advantageous, such as in peptide-based 
cytotoxic cancer therapy (Boerman, et al., 2000). The half-life of small peptides can also 
be extended using a variety of techniques, like glycosylation (Haubner et al., 2001) and 
serum albumin association (Koehler et al., 2002). Small molecule mimics of peptide 
ligands have been shown to compete and interfere with the binding of natural ligands of 
receptor-mediated binding interactions of therapeutic interest; for instance, in receptor- 
mediated binding that takes place in both the gastrointestinal and neuro-cranial systems 
(Mizejewski, 2001). Synthetic peptides can also provide the basis for the development of 
novel pharmaceuticals, such as drugs that are non-peptide in nature that mimic the actions 
of the peptide ligand. The low molecular-weight TIR peptide mimic of the TIR domain 
[(F/Y)-(V/L/I)-(P/G)] of the MyD88 adaptor protein involved in TLR signaling, has been 
shown to have a significant effect upon EL4 thyoma cells and murine lymphocytes. The 
TIR peptide mimic inhibited MAP kinase p38 phosphorylation by IL-lbeta, and also led 
to a reduction in IL-1 beta-induced fever responses in mice (Bartfai et al., 2003). The 
ability of a three-residue peptide mimic to have a significant biological effect indicates 
that it is possible to develop small peptide mimics from TLR ligands that have a 
significant therapeutic effect.
Specific Aims
The aim of this thesis project was to determine whether the five TLR2-LRR-binding
12
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peptides synthesized based on the previous FliTrx™ study can have a significant 
biological effect on TLR2 activation in vitro. The biological effect of these peptides was 
tested, by examining their ability to induce BMDC maturation and macrophage activation 
in a series of in vitro assays.
The effect of the synthetic peptides on in vitro maturation of BMDCs was 
evaluated by flow cytometry and cytokine analysis. In this study, we determined that 
one synthetic peptide, JT1, significantly activated the BMDCs in vitro, as measured by 
increased IL-6 production and upregulation of the MHC class II marker. In contrast, we 
found that none of the peptides tested modulated the binding of Salmonella typhimurium 
to human macrophages. Finally, a TLR screening assay performed by an outside 
consultant (Invivogen Corp.) found that no significant upregulation of NF-kB occurred 
by TLR2 in response to any of the synthetic peptides.
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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Table represents the identities and specific sequences of the 5 peptides used in this study. 
These peptides were chosen based on a preliminary study in which they were shown to 
physically bind to the LRR of TLR2.




Bone Marrow-Derived Dendritic Cells
Femurs removed from two adult C 57 Black 6 micewerewashed by briefly 
soaking 15-ml of Roswell Park Memorial Institute (RPMI) 1640 medium. They were 
then transferred transferred to a sterile petri dish and soaked in 70% ethanol for two to 
three minutes, followed by two additional washes with RPMI 1640 medium. The femurs 
were transferred to a sterile petri dish and placed in a laminar flow cell culture hood and 
flushed with cold RPMI 1640 using a sterile 20-gauge needle attached to a 3cc syringe 
and the bone marrow was strained through a 40-p.m cell strainer. The cells were pelleted 
at 1,000 x g for 10 minutes and resuspended in 10 mL of RPMI 1640 containing 5% 
granulocyte macrophage colony-stimulating factor (GMCSF) as a conditioned 
supernatant (GMCSF was a generous gift of the Brent Berwin laboratory. Dartmouth 
Medical School), 1% penicillin streptomycin, and 10% fetal bovine serum (FBS). The 
cells were again pelleted at 1,000 x gravity for ten minutes and resuspended in 5 mL of 
supplemented RPMI 1640. We maintained Primary BMDC cultures were for a total of 
eight days. On day zero the cells were seeded at approximately 0.5-1.0 x 106 cells/mL in 
a 24-well plate. The cells were washed and new medium was added every two days, with
16
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stimulations occurring on day six.
U937 Culture
The U937 cells used in this study were purchased from the American Type 
Culture Collection (ATCC, #CRL-1593.2)) and were grown in 5% CO2 at 37°C. The 
supplemented media used was RPM I1640 with 1% Penicillin and Streptomycin and 5% 
FBS. The cells were passaged every 4 to 5 days. The cells were fed every two days by 
addition of 15 mL of media to each flask.
TLR2-LRR-Binding Peptides
Synthetic peptides JT1-JT5 (Table 1) were synthesized and HPLC purified by EZ 
Biolab, Inc (Westfield, IN). Peptides were greater than 95% pure as determined by mass 
spectrometry analysis. Peptide stock solutions for this study were made by dilutions with 
endotoxin free water. All peptide dilutions were tested for endotoxin contamination 
using a Cambrex Limulus amebocyte lysate (LAL) (Pyrogent Plus™) gelation assay kit. 
Maximum levels of endotoxin contamination for peptides diluted to lOOpg/mL were less 
than 60 EU/mL. Because peptide JT1 was determined to activate BMDCs in our studies, 
a follow up endotoxin test of JT1 was conducted by the Associates of Cape Cod 
commercial laboratory, using kinetic chromogenic characterization. JT1 endotoxin levels 
as determined by the Associates of Cape Cod was .04-.06 EU/pg or 4-6 pg/mL. The 
lowest reported stimulation level for antigen presenting cells is 15 pg/mL (Reed, Berwin, 
Baker and Nicchitta, 2003).
Stimulation of Cells
The BMDCs were stimulated on the sixth day after explantation, using several 
different stimuli that included the non-biotinylated synthetic peptides JT1-JT5,
17
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biotinylated versions of peptides JT1-JT5 with or without streptavidin cross-linking and 
LPS as a positive control. Initial experiments were performed using a variety of cell 
densities and peptide concentrations in an effort to determine optimal conditions for 
stimulation.
Thereafter, stimulations with the non-biotinylated peptides consisted of using 
each peptide at a concentration of approximately 50 pg/mL. The individual peptides 
were added to wells on the 24-well plate on day 6 after washing and feeding had been 
performed. The cells were allowed to incubate with the peptides for 36-48 hours. After 
incubation, the supernatants from each well were saved and the cells were harvested for 
analysis via flow cytometry. Cell harvesting consisted of repeated pipetting of the 
medium to loosen cells, then transferring the suspended cells to flow cytometry tubes. 
The tubes were centrifuged at 250x gravity for 10 minutes to allow the cells to pellet and 
the supernatant was collected and saved for analysis, and the cells were resuspended in 
lx PBS to be stained for flow cytometry.
Biotinylated Peptides
The five synthetic peptides were biotinylated using the Pierce EZ-link ™ Sulfo 
NHS-LC Biotin kit according to the manufacturer’s directions. The biotinylated peptides 
were separated from the biotinylating reagents using a 1-ml gel filtration column 
(sephadex G-15 resin, Sigma Product #G-15-120).
Cross-Linked Peptides
The biotinylated peptides were cross-linked using Neutravidin™-coated beads 
(Pierce) as follows. A packed volume of 250 pL of beads was placed in a sterile 
microcentrifuge tube together with approximately 1 mL of the biotinylated peptides at a
18
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concentration of about lmg/mL. Each protein-bead slurry was rocked at room 
temperature for 30 minutes; the beads were then washed with sterile 1 x PBS and 
resuspended in a 1:1 solution with cell culture medium. 250 pL from the final slurry 
suspension was added to individual wells of a 24-well culture plate. The cells were 
incubated for 36 to 48 hours and the supernatants were removed for cytokine analysis. 
Invivogen NF-kB Study
The NF-kB activation study was performed by the Invivogen Corporation using a 
secreted alkaline phosphatase reporter gene under the control of a promoter induced by 
the activated NF-kB transcription factor. Details of the assay are available on the 
Invivogen Corporation website (www.invivogen.com). The stimulation of TLRs was 
assessed by measuring the NF-kB activation in HEK293 cells in response to each of the 
JT peptides. A panel of HEK293 cells transfected with individual TLRs 2,3,4,5,7,8 and9 
was used and involved testing each TLR against all five peptides. A 96 well plate was 
seeded with 2.5-5.0 x 104 cells/ well with 20 pi (50pg/ml) of experimental peptide added 
for a total volume of 200 pi. The cells were incubated for 16-20 hours at 37°C and OD650 
was determined using a Beckman Coulter AD 340C Absorbance Detector. The assay for 
each peptide was performed in duplicate and data were compared against a panel of 
positive control reagents specific for a panel of TLRs.
Salmonella Binding Assay
The U937 macrophage cells were activated by adding 1 x 10"9 M phorbol myristic 
acid (PMA) to the culture. Cultures were then incubated for 24 hours, and the cells were 
washed 3x with unsupplemented RPMI to remove the PMA. The cells were resuspended 
to a final concentration of 3x 105 cells/ml and 300 pi of the solution was seeded into each
19
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well of an 8-chambered Lab-Tek ““ glass slide. One of the experimental peptides was 
then added to each well at a concentration of approximately 100 pg/mL, with the 
exception of peptide JT1, which was added at -33 pg/mL due to limited quantities of 
peptide. The slides incubated at 37°C for 2 hours to allow the U937 cells to attach. The 
culture of Salmonella typhimurium was prepared by growing the cells aerobically for 8 
hours, then inoculating 20 mL of media with 1 mL of the initial culture and incubating it 
anaerobically for -24 hours. The bacterial cells were washed 3x in lx HBSS and 
resuspended in 10 ml of lx Hanks Buffered Salt Solution (HBSS), giving a concentration 
-lx lO 9 bacterial cells/ml. The U937 cells were incubated for two hours and the 
Salmonella were added at a concentration of -3xl07 cells/ml in seven of the eight wells. 
A chamber without bacteria was the negative control. The slides were incubated for 1 
hour and stained differentially by the hemostat staining technique and viewed using a 
light microscope at lOOOx oil immersion.
Toxicity Test
Toxicity testing of the five synthetic JT peptides was done using the U937 cell 
line. Approximately 2 ml of a 2.0xl05 cells/ml solution was seeded into three sets of six 
culture tubes (18 tubes total). We added each peptide to three tubes, at a concentration of 
lOOug/ml. We incubated the cells and determined viability at three intervals using one 
set of six tubes, (5 experimental and 1 control with no peptide) as one time point. Counts 
were done at 24, 48 and 65 hours using trypan blue exclusion dye.
Cytokine Analysis
All cytokine analysis was performed by the Dartmouth Hitchcock Medical 
Centers Immune Monitoring facility. Supernatant from stimulated BMDCs were loaded
20
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onto a 96 well plate and were analyzed for cytokine content through multiplex enzyme- 
linked immunosorbant assays (ELISA) and quantified using a Luminex array reader at 
ODg5o.
21
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CHAPTER III
RESULTS
Toxicity Testing of TLR2-LRR binding peptides.
In vitro toxicity testing of the TLR2-LRR binding peptides was performed via 
growth curve analysis using the U937 cell line. We did not observe a significant decline 
in cell numbers in response to addition of the synthetic peptides at 100 pg/mL. The 
viability of the cells growing in the presence of the peptides JT3 and JT4 was 
approximately 30% lower than that of the other experimental groups after 48 hours. 
However, since no significant decline in cell viability was observed after the 24 hour 
incubation period relative to our experiments (Figure 5), we concluded that the peptides 
were not toxic and that stimulation experiments could proceed.
Flow Cytometry Analysis
Flow cytometry analysis revealed that newly explanted bone marrow cells (figure 
6) were significantly smaller than the same cells after 6 days incubation with GMCSF, 
and had lower percentage of BMDCs based on staining for the CD1 lc dendritic cell 
marker. The day six cells were more consistent in their forward and side-scatter profiles, 
which is typical of expansion BMDC’s in culture with GMCSF (BrentBerwin, personal 
communication). Low-level activation of the CD1 lc positive cells in response to peptide 
JT1 was observed by flow cytometry staining for the MHC class II maturation marker in 
several replicate experiments. No significant stimulation, as measured by increased
22
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Figure 5. Growth of U937 Ceils in the Absence or Presence of TLR2- 
LRR Binding Peptides


















Graphical representation of the growth of U937 cells (thousands) in vitro with respect to 
time (hours) in the presence or absence of the 5 experimental JT peptides and a control 
(unstimulated) group. This graph represents a single trial of this experiment.
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Figure 6.Forward Scatter Versus Side Scatter Profiles of Day 0 and Day 
6 BMDCs.
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This figure displays the forward versus side scatter flow cytometry profiles performed on 
freshly explanted (day 0) or after 6 days in culture with GMCSF. Day 6 cells were 
larger in size and exhibited increased granularity and were more positive for the CD1 lc 
BMDC marker. The R1 region is the region containing the cell population of interest.
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Figure 7.MHC-CIass II Upregulation of Day 6 BMDCs in Response to 
stimulation with Peptide JT1.
o  _
FL1-H
A comparison between stimulated (solid line) and unstimulated (broken line) 
BMDC when stained with FITC conjugated MHC class II antibody. In this experiment, 
day 6 BMDCs were cultured for 36 hours in the presence or absence of peptide JT1 @ 50 
pg/ml. Flow cytometry profiles are for cells on region (Rl, figure 7) positive for the 
CD1 lc BMDC marker. In this experiment only 11.8 % of the unstimulated cells fell into 
the MHC class II very bright population (indicated by marker M2), relative to 22.9 % of 
the stimulated population. The median brightness of unstimulated cells positive for the 
MHC class II BMDC maturation marker (as indicated by marker M l) was 172; compared 
with the median brightness of stimulated cells which was 319.
25
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Table 2.Compilation of Flow Cytometry Data
JT1 JT2 JT3 JT4 JT5 No stim LPS
Cell Density M2%+ M1 M2%+ M1 M2%+ M1 M2%+ M1 M2%+ M1 M2%+ M1 M2%+ M1
5.00 E5 / well 
50ug/ml
7.4 116.0 11.0 173.0 7.1 131.0 12.0 179.0
7.6 141.0
1.00 E6 / well 
50ug/ml
10.6 154.0 14.8 207.0 13.0 178.0 7.3 146.0
7.4 122.0 17.4 228.0 7.5 126.0 17.6 225.0
15.9 219.0 12.6 173.0
1.50 E6 / well 
50ug/ml
22.9 319.0 3.4 45.7 5.0 50.0 2.8 41.0 13.4 188.0 11.8 172.0 14.5 220.0
15.2 183.0 2.9 43.0 8.0 52.3 7.5 54.0 11.3 165.0 14.0 107.0
15.1 80.6 2.0 43.5 7.0 53.2 13.6 113.0
10.2 64.4 7.4 55.2
1.4 36.2
2.00 E6 / well 
50ug/ml
5.6 73.0 7.0 101.0 6.4 82.0 12.2 143.0 4.8 84.3 5.7 88.2 13.4 142.0
25.3 161.0 8.6 99.0 10.3 115.0 10.3 107.5 7.0 96.5 11.0 121.9 19.9 184.0
2.00 E6 / well 
100ug/ml
5.5 81.3 7.0 97.3 5.7 84.3 10.0 119.7 4.5 82.0 5.7 88.2 13.4 142.0
1.00 E6 / well 
10ug/ml
6.5 45.3 5.4 51.9 6.7 50.7 8.0 61.5 8.4 47.0 6.1 52.8 23.5 191.0
This chart represents a compilation of single peptide flow cytometry data. The data in the 
far left column represents the approximate BMDC density used in each well of a 24-well 
culture plate as well as the concentrations of the peptides used in the experiments. Each 
row represents the data collected for that particular density and peptide concentration.
The data in each peptide column represent the percentage of gated cells that fell into the 
M2 shoulder population (left), and the median brightness levels in the gated population 
(right) for peptides JT1-5, unstimulated cells, and cells stimulated with LPS at 50 pg/mL. 
Blank cells indicated no data.
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upregulation of MHC class II relative to non-stimulated controls was observed for the 
other peptides tested, JT2,3 and 4. peptides and negative control group. Figure 6 shows 
an increase in median brightness (FLI) of cells stimulated with peptide JT1 relative to 
unstimulated controls. The unstimulated control group showed a greater percentage of 
cells at a peak median brightness of 102 units (FLI) than the JT1 stimulated cells 103-104 
units (FLI).
The stimulation data collected in multiple flow cytometry experiments exhibited a 
great deal of variability largely correlated with BMDC density (Table 2). Our data 
suggest that 1.5xl06 cells/mL was the most appropriate cell density for these experiments 
based upon observed greater sensitivity to LPS. Cells plated at this density showed the 
most consistent activation in the presence of peptide JT1 (Table 2).
During 12 flow cytometry experiments, peptides JT2-5 showed no MHC class II 
activation, having data similar to that of the negative control. The flow cytometry 
experiments staining for the upregulation of the B7 co-stimulatory marker were negative 
for all peptides, including JT1 as well as the LPS positive control.
Cytokine Analysis
The supernatants from the BMDCs stimulated in vitro with TLR2-LRR-binding 
peptides were analyzed for levels of IL-6, IL-8, IL-ip, IL-12 and TNF-a. The cytokine 
analysis of the supernatants of cells stimulated with JT1 indicated showed significant 
levels of IL-6 in comparison to the unstimulated control (Figures 8 and 9). Statistical 
analysis of these data using a student’s t-test with 13 degrees of freedom resulted in a t 
value of 1.42, suggesting that the difference between the JT1 values and the unstimulated
27
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Figure 8. Frequency of IL-6 Secretion in Response to Peptides JT1-JT5
IL-6 SN Data
o 0.8
No LPS JT1 JT2 JT3 JT4 JT5
B 5x no stim 
■  20x no stim
Stimulations
This is a graphical representation of the supernatant data collected for IL-6. Supernatants 
derived from BMDCs cultured with LPS, no peptides, or peptides JT1-JT5 were analyzed 
for IL6 as described. Bars represent the frequency of wells in each experimental group 
for which the IL-6 level detected (pg/mL) was greater than 5x (blue) or greater than 20x 
(red) the baseline detection level of 5 pg/mL. Number of replicate wells tested for each 
experimental group is indicated above the bars. All peptides stimulated a low level 
increase in IL-6 production, with the exception of JT5.
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Figure 9. IL-6 Secretion in Response to Peptides JT1-JT5.



















•  JT5 
+ LPS
This graph is a log scale representation of the supernatant data collected for each of the 5 
JT peptides as well as the two control groups in reference to IL-6 production. Values are 
based on multiplex spectrophotometric assay at ODgso- Based on these results, peptide 
JT1 was determined to be stimulatory for IL-6 production in several replicate 
experiments.
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No LPS JT1 JT2 JT3 JT4 JT5 
stim
Stimulations
H5x no stim 
■20x no stim
This is a graphical representation of the supernatant data collected for IL-8. Supernatants 
derived from BMDCs cultured with LPS, no peptides, or peptides JT1-JT5 were analyzed 
for IL-8 as described. Bars represent the frequency of wells in each experimental group 
for which the IL-8 level detected (pg/mL) was greater than 5x (blue) or greater than 20x 
(red) the baseline detection level of 5 pg/mL. Number of replicate wells tested for each 
experimental group is indicated above the bars. Secretion of IL-8 did not occur in 
response to peptides JT2, 3,4 and 5.
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Figure 11. IL-8 Secretion in Response to Peptides JT1-JT5.
















•  JT5 
+ LPS
This graph is a log scale representation of the supernatant data collected for each of the 5 
JT peptides as well as the two control groups in reference to IL-8 production. Values are 
based on multiplex spectrophotometric assay at OD eso-
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values are significantly different at a .179 confidence interval. The levels of IL-6 
produced in response to JT1 were 5x and 20x times the lowest detection level limit at 
frequencies of 0.36 and 0.29 respectively (n=14 experimental wells), in contrast to the 
observed frequencies for the unstimulated control group at 5x and 20x which were .07 
and .07 respectively (n=14), and 100% of all wells stimulated with LPS exhibited IL-6 
levels greater than 20x the background detection level (n=l3). Some increased IL-6 
activation was also seen with peptides JT2, 3, and 4, but not with JT5 (Figure 8).
The levels of IL-8 produced in response to JT1 had 5x and 20x the baseline 
detection limit at frequencies of 0.21 and 0.14. In contrast no increased IL-8 production 
was observed in response to JT2,3,4 and 5 (figure 10).
No increased production of IL-12 or IL-ip for BMDCs cultured with any of the 
JT peptides. Increased production of IL-12 (Figure 12) occurred only in response to LPS. 
Production of IL-lp (Figure 13) was not detectable in response to any of the stimuli.
Cytokine results for TNF-a (figure 14) were positive in response to JT1 and JT2. 
We found frequency stimulation values 5 and 20 times the baseline detection limit at 
frequencies .21 and .21 for JT1, and .22 and .11 for JT2. The activation in response to 
these peptides was not statistically significant.
Invivogen NF-ieb Study
The Invivogen Corporation determined NF-kB activation did not occur at a 
significant level in response to the TLR2-LRR-binding peptides. The assay used 
individual HEK293 cell lines expressing seven different TLRs: TLR2,3,4,5,7,8 and 9 
(Table 3; Figure 15). NF-kB Activity was monitored by measuring the OD650 of a 
secreted alkaline phosphatase reporter, which was induced by NF-kB. This assay was
32
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Figure 12. IL-12 Secretion in Response to Peptides JT1-JT5.


















This graph is a log scale representation of the supernatant data collected for each of the 5 
JT peptides as well as the two control groups in reference to IL-12 production. Values 
are based on multiplex spectrophotometric assay at OD650-
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Figure 13. IL-ip Secretion in Response to Peptides JT1-JT5.


















•  JT5 
+ LPS
Peptides
This graph is a log scale representation of the supernatant data collected for each of the 5 
JT peptides as well as the two control groups in reference to IL-1B production. Values 
are based on multiplex spectrophotometric assay at ODgso.
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Figure 14. TNF-a Secretion in Response to Peptides JT1-JT5.















•  JT5 
+ LPS
This graph is a log scale representation of the supernatant data collected for each of the 5 
JT peptides as well as the two control groups in reference to TNF-a production. Values 
are based on multiplex spectrophotometric assay at OD 650.
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Table 3, Results of Invivogen NF-kB Study
Results
Result; are provided as O 0  <650ruii'i values 




Ligand JT1 JT2 JT3 1T4 JT5 Control +
hTLR2 0.091 0.144 0.109 0.141 0.093 0.097 2.654
hTLR3 0.161 0.154 0.163 0.142 0.150 0.130 2.454
hTLR4(MD2-CD14) 0.090 0.093 0.081 0.079 0.080 0.076 2.187
hTLRS 0.113 0.133 0.143 0.163 0.115 0.120 2.826
HTLR7 0.075 0.074 0.070 0.063 0.071 0.065 2.356
hTLRS 0.160 0.139 0.144 0.146 0.145 0.136 2.165
hTLR9 0.159 0.123 0.116 0.109 0.116 0.118 2.612





Liaand JT1 JT2 3T3 JT4 3T5 Control +
hTLR 2 0.106 0.174 0.119 0.155 0.111 0.105 2.813
hTL R 3 0.137 0.115 0.144 0.128 0.119 0.119 2.749
h T L R 4 (K D 2 -C D 1 4 i 0.095 0.090 0.099 0.081 0.081 0.075 2.837
HTLR5 0.183 0.192 0.202 0.218 0.166 0.190 2.973
h T L R ? 0.116 0.097 0.100 0.104 0.096 0.094 2.698
hTLRS 0,196 0.146 0.167 0.158 0.148 0.151 2.093
hTLRS 0.124 0.101 0.106 0.103 0.106 0.099 2.172
P a r e n t  c e lls 0.109 0.098 0.103 0.101 0.095 0.098 2.438
Final concentration : f  :,'.n:;'lr: SC^s'taL
Tables represent two identical screenings measuring NF-kB activation at OD650 as 
described in materials and methods. The activation of peptides JT1 through 5 and their 
effect on hTLRs: 2, 3,4, 5, 7, 8, and 9.
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Figure 15. Graphical Results of NF-kB Study
The values on die graph corresponds to an average of screening 1 and 2
TLR Ligand Screening




■  JT4 
SSJT5









Final concentration of samples is SO^g/mL
Control ligands hTLR2: HKLM (heat-killed listeria monocytogenes) at 10s cells/ml
hTLR3: Poly(I:C) at 1 ;<g/ml 
hTLR4: E. coll K12 LPS~at 100 ng/ml 
hTLR5: S. typhimurium flagellin at 1 ;«g/ml 
hTLR7: Loxoribine at 1 mM 
hTLR8: ssRNA40 at 5 /cg/mL 
hTLR9: CpG ODN 2006 at 1 /rg/ml
Parent cells: PMA 10/ig/tnL (parent cells have no TLR and serve as control)
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marginally positive in response to JT l, 2 and 3 through TLR2, however this effect was 
not statistically significant. The response to peptides JT4 and JT5 was negative, with 
values at or below the unstimulated control cells. Of the three peptides that did show 
some low level activity in duplicate screenings, the most activity was observed in 
response to JT l. There was no activation seen through TLRs 3,4,5,7,8, and 9 in response 
to any of the peptides.
Salmonella Binding Assay
The Salmonella binding assay indicated that the JT peptides are not stimulatory to the 
U937 cells, and that the JT peptides do not block the binding of a natural TLR2 ligand 
(Table 5).
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JT l 33pg/mL 26% 3
JT2 lOOpg/mL 14% 2.7
JT3 lOOpg/mL 10% 2
JT4 lOOpg/mL 8% 2
JT5 100pg/mL 8% 2
No Peptide 4% 2
No Peptide 16% 2






JT l 100 pg/mL 38% 4.4
JT l 6 7 pg/mL 56% 4.2
JT l 33pg/mL 44% 3.1
JT l 17pg/mL 50% 4.
JT l lmg/mL 54% 4.4
No Peptide 42% 3
No Peptide 42% 3
No Bacteria 12% 2.3
Experiment 1 summarizes data gathered from the Salmonella binding to U937 cells in 
response to the five JT peptides. Experiment 2 summarizes the data gathered when U937 
cells were stimulated with varying concentrations of peptide JT l. Percentages represent 
the number of U937 cells positive for 2 or more bound Salmonella. The phagocytic 
index represents the average number of bound Salmonella to positive U937 cells.
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CHAPTER IV
DISCUSSION
The objective of this thesis was to evaluate the biological effect of five synthetic 
TLR2-LRR binding peptides through flow cytometry and cytokine profiling. We 
hypothesized that the peptides may be able to either elicit, or down-regulate an innate 
immune response, as has been seen with a small peptide TIR mimic (Bartfai et al 2003). 
The flow cytometry results showed variable BMDC activation in response to JTl and the 
cytokine analysis indicated that JTl induces IL6 production. The assay performed by 
the Invovogen Corporation determined that no significant NF-kB upregulation occurred 
in response to the peptides.
Flow Cytometry
Although the results of the BMDC stimulation experiments were variable and 
dependent on cellular density, peptide JTl was found to induce BMDC maturation in 
multiple experiments. At cell densities of 1.5xl06 cells/well and peptide concentrations 
of 50 pg/mL peptide JTl was as effective as LPS in upregulation of MHC class II. The 
MHC class II very bright population (indicated by M2 in Figure 6) averaged 15.8% 
(Table2, n=4) for JTl, and 14.0% (n=3) for LPS, versus 7.7% (n=5) for unstimulated 
controls. In contrast, BMDCs stimulated with peptides JT2-5 were not significantly 
different from unstimulated controls in selected experiments. Some stimulation of 
BMDCs plated at l.OOxlO6 and 2.00x106 cells/well was also observed.
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We observed an inconsistent stimulatory effect in response to peptide JTl at a 
concentration of 50pg/mL. Cell counting was performed before seeding the cells, but 
some variation in cell densities occurred, causing variability in BMDC activation 
experiments. Variability of BMDC cultures has been observed in the Berwin lab 
(personal communication) because of “over-handling” of cells, such as feeding and 
washing, causing the BMDCs in culture to activate. The peptides may have formed 
multimeric complexes, varying activation results. This would be difficult to control as 
several independent dilutions of the peptides were used. In order for consistent activation 
to be seen, it may be necessary to cross-link the peptides.
We performed most of our stimulations with peptide JTl, due to early success in 
its activation of BMDCs. More assays with the other JT peptides may have shown 
eventual BMDC activation. Future work would include further experimentations with the 
other synthetic peptides and a repeated attempt to cross-link.
Stimulated BMDCs were also stained for flow cytometry using the B7 maturation 
marker, but no activation was observed in response to the peptides or LPS. Upregulation 
of the B7 co-stimulatory marker may require more optimal conditions, or may occur 
through an independent pathway than through TLR2. Due to time constraints, we used 
the MHC class II marker for BMDC maturation, as we had already seen activation of this 
marker in response to the peptides and LPS control.
We designed several lab experiments to examine the effects of cross-linking of 
the peptides on BMDC activation. One experiment was designed based on streptavidin’s 
four biotin binding sites. Biotinylated peptides were added to BMDCs being cultured in 
streptavidin coated wells. Flow cytometry data indicated that no activation had occurred
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in response to any of the peptides. This required using a 96 -well plate system instead of 
24-well plates. This added variable changed the conditions of the cells being cultured, 
and was not optimized due to time constraints. Any future efforts with these peptides 
would involve more focus on cross-linking.
Attachment of the peptides to streptavidin-agarose beads was performed to cross­
link the peptides, such that the beads would represent a type of psuedo-bacterium. The 
large size of the beads was inappropriate for flow cytometry analysis because of bead 
auto-fluorescence (Alice Givan, personal communicatio). Cytokine* analysis of these 
supernatants yielded no positive results. The results do not necessarily indicate that 
cross-linking of the peptides cannot activate the cells; it is more likely that the 
preliminary cross-linking performed in lab were not optimal. Another variable is the 
degree of biotinylation of the peptides. If these experiments were to be repeated, the 
peptides would be commercially synthesized and biotinylated for consistency. Another 
possibility would be to use smaller beads more appropriate for flow cytometry analysis. 
Cytokine Analysis
The supernatants for all stimulation experiments underwent cytokine analysis at 
the DHMC Immune Monitoring Facility. All supernatants were examined for a series of 
cytokines, which included IL-6, IL-8, IL-1B, IL-12 and Tumor Necrosis Factor Alpha 
(TNF-a). In these assays, IL-6 was consistently and significantly upregulated when cells 
were cultured in the presence of JT1. We evaluated this using a Students T-test and JT1 
treatment proved to be statistically significant compared to the unstimulated control (t- 
value of 1.42, n=13); the confidence interval was 0.179, indicating less than a 20% 
chance that the observed difference was due to random sample error. These data
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represent two different screenings for IL-6 with 14 individual test wells where JT1 was 
used to activate the BMDCs. We interpret these results as positively indicating that JT1 
does play a biological role in the upregulation of IL-6 by BMDCs.
Some low level IL-6 production was observed in response to peptides JT2, 3, and 
4. This indicates that activation of IL-6 was a specific effect of JT1 and not just due to 
the presence of a foreign peptide in culture. More data points could have strengthened 
the statistical analysis as several experiments of poor activation data in regards to the 
positive control were included in the T-test.
The IL-8 cytokine analysis indicated marginal activation with JT1, but not with 
any of the other peptides, however this effect was not found to be statistically significant. 
Slight TNF-a production was also seen in response to JT1 and JT2. The analysis for IL- 
12 and IL-lb was negative for all the peptides. The ability of some peptides to 
upgregulate certain cytokines and not others indicates the specificity of the cytokine 
profiles produced in response to particular PAMPs.
Invivogen Studies
Because the stimulation of all TLRs is known to result in upregulation of the NF- 
kB transcription factor, making it was of interest to determine whether the JT peptides 
could also activate NF-kB. In assays performed for this study by the Invivogen 
Corporation, translocation of NF-kB was observed in cells expressing only TLR2, in 
response to co-culture with peptides JT1, 2 and 3. The effect was only slight, with the 
most activation observed in response to peptide JT1. When compared to the positive 
control groups the degree of activation in response to these peptides was statistically 
insignificant. However, in duplicate assays, the response was clearly greater than that
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seen with the negative control, therefore JT1 may have some minimal biological effect on 
TLR2 activation. In future studies, it would be of great interest to determine whether 
activation of NF-kB would be enhanced by biotinylated peptides if optimally cross- 
linked. It is possible that the NF-kB results observed reflect lack of optimization of the 
assay.
Salmonella Binding Assay
The Salmonella binding assay was performed to examine the ability of the 
peptides to effect the binding of the human macrophage U937 cell line to Salmonella 
typhimurium by using all five synthetic peptides, as well as a negative control containing 
no peptide, and a control that contained only U937 cells. The only peptide that increased 
increase both the phagocytic activity as well as the phagocytic index of the macrophages 
was JT1. This peptide was added at a lower concentration (33pg/mL) due to low 
amounts of stock JT1. An experiment with varying concentrations of JTI, did not 
indicate an increase in binding of bacteria at a significant level. If this were repeated, 
another attempt would be made to optimize the amount of peptide required to effect U937 
binding. The peptides do not block the binding of a natural ligand and there was no 
difference between the positive control cells and peptides JT2, 3, 4 and 5 in regards to 
phagocytic activity or index.
More careful testing is needed, as the negative control cells that contained no 
bacteria were positive for some binding. I was careful to maintain proper aseptic 
technique but some contamination of the wells did occur. This was likely due to the 
close proximity of the wells containing the bacteria with the negative control well and 
that the same reagents were used for all wells.
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Future Directions
Based on the results of this study, we anticipate that cross-linking the peptides is 
likely to be the most effective way to continue studying the biological role of the JT 
peptides in BMDC activation. Experiments involving different functional endpoints, 
such as cell division, or the up-regulation of other cell surface markers would also be 
appropriate, as would flow cytometry experiments which focus on staining for the B7 co­
stimulatory markers.
Since only JT1 was observed to have a biological function and not JT2,3,4,or 5, 
the conclusion can be drawn that the motif (GxxV/L/I) was not relevant. All of the 
peptides had the same number of residues and only differed in the location of the motif 
and the residues that surrounded it. If the motif allowed the peptides to interact with 
TLR-2, all of the peptides should have caused BMDC maturation and cytokine secretion. 
Future work with these peptides could determine why JT1 has a biological effect, while 
the other peptides do not. This could be done by substitutions and deletions in the JT1 
peptide sequence.
The IL-6 cytokine results and other data collected from stimulations with peptide 
JT1 a significant biological role. Other published TLR studies have only determined the 
ligands responsible for TLR activation at the macromolecular level (Bulut, 2001, Hajjar, 
2001, reviewed in Takeda and Akira, 2001) and not the specific peptide sequences 
involved. It is known that activation of the TLRs upregulates NF-kB production 
(Hallman et al., 2001), what is not known is how a ligand is able to shape cytokine 
profiles.
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We have shown that IL-6 production occurs in response to peptide JT1, and not 
the other peptides. Of the several cytokines we looked at, IL-6 was the only one 
produced in response to JT1 at a significant level. IL-6 was initially thought to be only 
be an inflammatory cytokine, however it has been shown to inhibit TNF-a production, as 
well as T-lymphocyte and macrophage function. The presence of IL-6 has also been 
shown to markedly reduce NF-kB activity and augment immunoglobulins (Wheeler et. 
al, 1999, Hegde et. al, 2004). Inhibition of inflammatory cytokines such as TNF-a has 
been shown to improve both organ function and survival in animal sepsis models 
(Wheeler et. al, 1999). The role of TLR2 activation in an immune response could be to 
downregulate an inflammatory immune response, while promoting an adaptive response 
to occur .
This study has increased the current understanding of ligand recognition by 
TLR2, as well as the ability of this receptor to shape an immune response through 
production of IL-6. This knowledge will be beneficial in future studies with TLRs, as 
well as in the development of novel peptide based therapeutics.
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
46
BIBLIOGRAPHY
Aderem, A, and KD. Smith. 2004. A systems approach to dissecting immunity and 
inflammation. Semin Immunol.
Akira, S. 2004. Toll Receptor Families: Structure and Function.
Semin Immunol 16
Aliprantis, A. O., D. S. Weiss, J. D. Radolf, A. Zychlinsky. 2001. Release of Toll-like 
receptor-2-activating bacterial lipoproteins in Shigella jlexneri culture supernatants.
Infect Immun 69(10): 6248-6255.
Anderson, K. V., G. Jurgens, C. Nusslein-Volhard. 1985. Establishment of dorsal- 
ventral polarity in the Drosophila embryo: genetic studies on the roll of the Toll gene 
product. Cell 42: 779-789.
Arbibe, L., J. -P. Mira, N. Teusch, L. Kline, M. Guha, N. Mackman, P. J.
Godowski, R. J. Ulevitch, and U. G. Knaus. 2000. Toll-like receptor 2-mediated NF- 
kappaB activation requires a Racl-dependent pathway. Nature Immunol 1: 533-540.
Armant, M. A., and M. J. Fenton. 2002. Toll-like receptors: a family of pattem- 
recognition receptors in mammals. Genome Biology 3(8): 3011.1-3011.6.
Bartfai, T., M. M. Behrens, S. Gaidarova, J. Pemberton, A. Shivanyuk, and J. 
RebekJr. 2003. A low molecular weight mimic of the Toll/IL-1 receptor/resistance 
domain inhibits IL-1 receptor-mediated responses. PNAS 100(13): 7971-7976.
Bell, J. K., G. E. D. Mullen, C. A. Leifer, A. Mazzoni, D. R. Davies, and D. M. Segal.
2003. Leucine-rich repeats and pathogen recognition in Toll-like receptors. Trends in 
Immunology 24(10): 528-533.
Boerman, O. C., W. J. Oyen, and F. H. Corstens. 2000. Radio-labeled receptor- 
binding peptides: a new class of radiopharmaceuticals. Semin Nucl Med 30: 195-208.
Buchanan, S. G., and N. J. Gay. 1996. Structural and Functional diversity in the 
leucine-rich repeat family of proteins. Prog Biophys Mol Biol 65: 1-44.
Caux, C., B.Vanbervliet, B. Dbuois, C.Van Kooten, I. Durand, and J.Banchereau.
1994. Activation of human dendritic cells through CD40 cross-linking. J Exp Med. 
180(4): 1263-72
Chen, R., L. H. Lim, H. Jono, X. X. Gu, Y. S. Kin, C. B. Basbaum, T. F. Murphy,
and J. D. Li. 2004. Nontypeable Haemophilus influenzae lipoprotein P6 induces 
MUC5AC mucin transcription via TLR2-TAK1-dependent p38 MAPK-AP1 and 
IKKbeta-IkappaBalpha-NF-kappaB signaling pathways. Biochem Biophys Res Commun 
324(3): 1087-1094.
47
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
Clark, L., P. Viswanathan, G. Quigley, Y.-C. Chiang, J. McMahon, G. Yao, A. 
Nelsbach, and C. Denis. 2004. Systematic mutagenesis of the leucine-rich repeat 
(LRR) domain of CCR4 reveals specific sites for binding to CAF1 and a separate critical 
role for the LRR in CCR4 deadenylase activity. J  Biol Chem 279: 13616-13623.
Clemetson, J., P. Kyrle, B. Brenner, and K. Clemetson. 1994. Variant Bemard- 
Soulier Syndrome Associated with Homozygous Mutation in the Leucine-Rich Domain 
of Glycoprotein IX. Blood 84(4): 1124-1131.
Darveau, R. P., T. T. Pham, K. Lemley, R. A. Reife, B. W. Bainbridge, S. R. Coats, 
W. N. Howald, S. S. Way, and A. M. Hajjar. 2004. Porphyromonas gingivalis 
lipopolysaccharide contain lipid A species that functionally interact with both toll-like 
receptors 2 and 4. Infect Immun 72(9): 5041-5051.
Dolganiuc, A., S. Oak, K. Kodys, D. T. Golenbock, R. W. Finberg, E. Kurt-Jones, 
and G. Szabo. 2004. Hepatitis C core and nonstructural 3 proteins trigger toll-like 
receptor 2-mediated pathways and inflammatory activation. Gastroenterology 127(5): 
1513-1524.
Dziarski, R., and D. Gupta. 2005. Staphylococcus aureus peptidoglycan is a toll-like 
receptor 2 activator: a reevaluation. Infect Immun 73(8): 5212-5216.
Fisher, J. R. 2004. Master’s Thesis: Isolation and characterization of CCR4-LRR 
binding peptides. University o f New Hampshire.
Fisher J. R., K. W. Donovan, E. Houde, J. Tierney, J. S. McMahon, C. L. Denis, and 
L. B. Clark. Unpublished-2004. Yeast CCR4-LRR-binding peptide aptamers contain a 
conserved motif analogous to ToML-lR/resistance (TIR) dimerization domain.
Fujita, M., T. Into, M. Yasuda, T. Okusawa, S. Hamahira, Y. Kuroki, A. Eto, T. 
Nisizawa, M. Morita, and K. Shibata. 2003. Involvement of Leucine Residues at 
Positions 107,112, and 115in a Leucine-Rich Repeat Motif of Human Toll-Like 
Receptor 2 in the Recognition of Diacylated Lipoproteins and Lipopeptides and 
Staphylococcus aureus Peptidoglycansl. J  Immunol 111: 3675-3683.
Gallop, M. A., R. W. Barrett, W. J. Dower, S. P. A. Fodor, and E. M. Gordon. 1993. 
Applications of combinatorial technologies to drug discovery. J  Med Chem 37(9): 1233- 
1251.
Giambartolomei, G. H., A. Zwerdling, J. Cassataro, L. Bruno, C. A. Fossati, and M.
T. Philipp. 2004. Lipoproteins, not lipopolysaccharide, are the key mediators of the 
proinflammatory response elicited by heat-killed Brucella abortus. J  Immunol 173(7): 
4635-4642.
48
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
Hajishengallis, G., M. Martin, H. T. Sojar, A. Sharma, R. E. Schiffcrle, E. 
DeNardin, M. W. Russell, and R. J. Genco. 2002. Dependence of Bacterial Protein 
Adhesins on Toll-Like Receptors for Proinflammatory Cytokine Induction. Clin Diagn 
Lab Immunol 9(2): 403—411.
Hajjar, A. 2001. Cutting Edge:Functional Interactions Between Toll-Like Receptor 
(TLR)2 and TLR1 or TLR6 in Response to Phenol-Soluble Modulin.
Cutting Edge
Hallman, M., M. Ramet, and R. A. Ezekowitz. 2001. Toll-like receptors as sensors of 
pathogens. Pediatric Research 50(3): 315-321.
Haubner, R., H. J. Wester, F. Burkhart, R. Senekowitsch-Schmidtke, W. Weber, S. 
L. Goodman, H. Kessler, and M. Schwaiger. Glycosylated RGD-containing peptides: 
tracer for tumor targeting and angiogenesis imaging with improved biokinetics. JNucl 
Med 42: 326-336.
Hegde, S., J. Pahne, S. Smola-Hess. 2004. Novel immunosuppressive properties of 
interleukin-6 in dendritic cells: inhibition of NF-kB binding activity and CCR7 
expression. JFASEB18: 1439-1441
Henneke, P., O. Takeuchi, J. A. van Strijp, H. K. Guttormsen, J. A. Smith, A. B. 
Schromm, T. A. Espevik, S. Akira, V. Nizet, D. L. Kasper, and D. T. Golenbock.
2001. Novel engagement of CD 14 and multiple toll-like receptors by group B 
streptococci. J  Immunol 167(12): 7069-7076.
Hertz, C. J., S. M. Kiertscher, P. J. Godowski, D. A. Bouis, M. V. Norgard, M. D. 
Roth, and R. L. Modlin. 2001. Microbial lipopeptides stimulate dendritic cell 
maturation via Toll-like receptor 2. J  Immunol 166(4): 2444-2450.
Houde, E. M. 2004. Master’s Thesis: Characterization of the specificity of peptides 
containing the motif (G/P)-(3)(L/V/I/F). University o f New Hampshire.
Into, T., Y. Nodasaka, A. Hasebe, T. Okuzawa, J. Nakamura, N. Ohata, and K. 
Shibata. 2002. Mycoplasmal lipoproteins induce toll-like receptor 2- and caspases- 
mediated cell death in lymphocytes and monocytes. Microbiol Immunol 46(4):265-276.
Iwaki, D., C. Nishitani, H. Matsuzawa, N. Hyakushima, H. Sano, and Y. Kuroki.
2005. The CD14 region spanning amino acids 57-64 is critical for interaction with the 
extracellular Toll-like receptor 2 domain. Biochem Biophys Res Commun 328(1): 173- 
176.
Iwaki, D., H. Mitsuzawa, S. Murakami, H. Sano, M. Konishi, T. Akino, and Y. 
Kuroki. 2001. The extracellular toll-like receptor 2 domain directly binds peptidoglycan 
derived from Staphylococcus aureus. J  Biol Chem 277(27): 24315-24320.
49
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
Janeway. Immuno Biology 6th edition.
Garland Science publishing 2005. New York, NY.
Kajava, A.V. 1998. Structural Diversity of leucine-rich repeat proteins. J  Mol Biol 
277: 519-527.
Kajava A., and B. Kobe. 2002. Assessment of the ability to model proteins with 
leucine-rich repeats in light of the latest structural information. Protein Science 11: 
1082-1090.
Kirschning, C. J., and R. R. Schumann. 2002. TLR2: Cellular sensors for microbial 
and endogenous molecular patterns. Curr Top Microbiol Immunol 270: 121-144.
Kobe, B. 1996. Leucines on a roll. Nat Struct Biol 3:/BO 977-980.
Kobe, B., and J. Deisenhofer. 1994. The leucine-rich repeat: a versatile binding motif. 
Trends Biochem Sci 19: 415-421.
Kobe B., and J. Deisenhofer. 1995. A structural basis of the interactions between 
leucine-rich repeats and protein ligands. Nature 374: 183-186.
Kobe, B. and A. V. Kajava. 2001. The leucine-rich repeat as a protein recognition 
motif. Curr Opin Struct Biol 11: 725-732.
Koehler, M. F., K. Zobel, M. H. Beresini, L. D. Caris, D. Combs, B. D. Paash, and R. 
A. Lazarus. 2002. Albumin affinity tags increase peptide half-life in vivo. Bioorg Med 
Chem Lett 12: 2883-2886.
Letiembre, M., H. Echchannaoui, F. Ferracin, S. Rivest, and R. Landmann. 2005. 
Toll-like receptor-2 deficiency is associated with enhanced brain TNF gene expression 
during pneumococcal meningitis. J  Neuroimmunol. in print.
Liang, M. D., A. Bagchi, H. S. Warren, M. M. Tehan, J. A. Trigilio, L. K. Beasley- 
Topliffe, B. L. Tesini, J. C. Lazzaroni, M. J. Fenton, and J. Heilman. 2005. Bacterial 
peptidoglycan-associated lipoprotein: a naturally occurring toll-like receptor 2 agonist 
that is shed into serum and has synergy with lipopolysaccharide. J  Infect Dis 191(6): 
939-948.
Liu, P. T., S. R. Krutzik, J. Kim, and R. L. Modlin. 2005. Cutting edge: all-trans 
retinoic acid down-regulates TLR2 expression and function. J  Immunol 174(5): 2460- 
2470.
Malvar, T., R. W. Biron, D. B. Kaback, and C. L. Denis. 1992. The Ccr4 protein 
from Saccharomyces cerevisiae contains a leucine-rich repeat region which is required 
for its control of ADH2 gene expression. Genetics 132: 951-962.
50
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
Mandell, L., A. P. Moran, A. Cocchiarella, J. Houghton, N. Taylor, J. Fox, T. Wang, 
and E. A. Kurt-Jones. 2004. Intact Gram-negative Helicobacter pylori, Helicobacter 
felis, and Helicobacter hepaticus bacteria activate innate immunity via Toll-like receptor 
2 but not Toll-like receptor 4. Infection and Immunity 72(11): 6446-6454.
Martin, G. and D. Mannino. 2003. The epidemiology of sepsis in the United States 
from 1979 through 2000. N Engl J Med 348: 1546-1554
Massari, P., P. Henneke, Y. Ho, E. Latz, D. T. Golenbock, and L. M. Wetzler. 2002. 
Cutting edge: Immune stimulation by Neisserial porins is Toll-like receptor 2 and 
MyD88 dependent. J  Immunol 168: 1533-1537.
Matsubara, Y., M. Murata, T Moriki, K. Yokoyama, N. Watanabe, H. Nakajima,
M. Handa, K. Kawano, N. Aoki, H. Yoshino, and Y. Ikeda. 2002. A novel 
polymorphism, 70Leu/Phe, disrupts a consensus Leu residue within the leucine-rich 
repeat sequence of platelet glycoprotein Ibalpha. Thromb Haemost 87(5): 867-872.
Meng, G., M. Rutz, M. Schiemann, J. Metzger, A. Grabiec, R. Schwandner, P. 
Luppa, F. Ebel, D. Busch, S. Bauer, H. Wagner, and C. Kirschning. 2004. 
Antagonistic antibody prevents toll-like receptor 2-driven lethal shock-like syndromes. J  
Clin Invest 113(10): 1473-1481.
Mitsuzawa, H., I. Wada, H. Sano, D. Iwaki, S. Murakami, T. Himi, N. Matsushima, 
and Y. Kuroki. 2001. Extracellular Toll-like receptor 2 region containing Ser40-Ile60 
but not Cys30-Ser39 is critical for the recognition of Staphylococcus aureus 
peptidoglycan. J  Biol Chem. 276(44): 41350-41356.
Mizejewski, G. J. 2001. Peptides as receptor ligand drugs and their relationship to G- 
coupled signal transduction. Expert Opin Investig Drugs 10(6): 1063-1073.
Muroi, M., T. Ohnishi, and K. Tanamoto. 2002. Regions of the mouse CD 14 
molecule are required for toll-like receptor 2- and 4-mediated activation of NF-kappaB. J  
Biol Chem 277(44): 42372-42379.
Muroi, M., T. Ohnishi, S. Azumi-Mayuzumi, and K. Tanamoto. 2003. 
Lipopolysaccharide-mimetic activities of a Toll-like receptor 2-stimulatory substance(s) 
in enterobacterial lipopolysaccharide preparations. Infect Immun 71(6): 3221-3226.
Nabel, G. J. 2002. HIV vaccine strategies. Vaccine 20(15): 1945-1947.
Osaki, K., D. J. Stearns-Kurosawa, K. Miyake, and S. Kurosawa. 2005.
Involvement of TLR2 in innate immune response to B. anthracis. FASEB 19(4): A379- 
A379.
Ozinsky, A., D. M. Underhill, J. D. Fontenot, A. M. Hajjar, K. D. Smith, C. B. 
Wilson, L. Schroeder, and A. Aderem. 2000. The repertoire for pattern recognition of
51
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
pathogens by the innate immune system is defined by cooperation between Toll-like 
receptors. Proc Natl Acad Sci USA 97(25): 13766-13771.
Paul, W. Fundamental Immunology. Third Edition.
Raven Press, New York. 1993.
Randolf, J. T., and D. A. DeGoey. 2004. Peptidomimetic inhibitors of HIV protease. 
Curr Top Med Chem 4(10): 1079-1095.
Ray, A., P. Karmakar, and T. Biswas. 2004. Up-regulation of CD80-CD-86 and IgA 
on mouse peritoneal B-l cells by porin of Shigella dysenteriae is Toll-like recptor 2 and 6 
dependent. Mol Immunol 41(12): 1167-1175.
Revets, H., G. Pynaert, J. Grooten, and P. De Baetselier. 2005. Lipoprotein I, a 
TLR2/4 ligand modulates Th2-driven allergic immune responses. J  Immunol 174(2): 
1097-1103.
Schoneveld, A. H., M. M. Oude Nijhuis, B. van Middelaar, J. D. Laman, D. P. de 
Kleijn, and G. Pasterkamp. 2005. Toll-like receptor 2 stimulation induces intimal 
hyperplasia and therosclerotic lesion development. Cardiovasac Res 66(1): 162-169.
Sehgal, A. 2002. Recent developments in peptide-based cancer therapeutics. Current 
Opinion in Drug Discovery and Development 5(2): 245-250.
Shimizu, T., Y. Kida, and K. Kuwano. 2005. A Dipalmitoylated Lipoprotein from 
Mycoplasma pneumoniae Activates NF-{kappa}B through TLR1, TLR2, and TLR6. J  
Immunol 175(7): 4641-4646.
Shockley, T. R., K. Lin, J. A. Nagy, R. G. Tompkins, H. F. Dvorak, and M. L. 
Yarmush. 1991. Penetration of tumor tissue by antibodies and other immunoproteins. 
Ann NY Acad Sci 618: 367-382.
Shuto, T., H. Xu, B. Wang, J. Han, H. Kai, X. X. Gu, T. F. Murphy, D. J. Lim, and
J. D. Li. 2001. Activation of NF-kappaB by nontypeable Haemophilus influenzae is 
mediated by toll-like receptor 2-TAK1-dependent NIK-IKK^p. ItcBa and MKK3/6-p38 
MAP kinase signaling pathway in epithelial cells. Proc Natl Acad Sci USA 98: 8774- 
8779.
Smith, G. P., D. A. Schultz, and J. E. Ladbuiy. 1993. A ribonuclease S-peptide 
antagonist discovered with a bacteriophage display library. Gene 128: 37-42.
Smits, G., M. Campillo, C. Govaerts, V. Janssens, C. Richter, G. Vassart, L. Pardo, 
and S. Costagliola. 2003. Glycoprotein hormone receptors: Determinants in leucine- 
rich repeats responsible for ligand specificity. EmboJ. 22: 2692-2703.
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
Takeda, K., and S. Akira. 2001. Roles of Toll-like receptors in innate immune 
responses. Genes to Cells 6: 733-742.
Takeda, K., T. Kaisho, and S. Akira. 2003. Toll-like receptors. Ann Rev Immunol 21: 
335-376.
Wheeler, A., Bernard, G. 1999. Treating Patients With Severe Sepsis. New Eng J  Med 
340: 207-214.
Wieland, T. 1995. The history of peptide chemistry. In Peptides: Synthesis, Structures 
and Applications (Gutte,B., ed.) Academic Press, pp. 1-38,
Xu, Y., X. Tao, B. Shen, T. Horng, R. Medzhitov, J. Manley, and L. Tong. 2000. 
Structural basis for signal transduction by Toll/interleukin-1 receptor domains. Nature 
408: 111-115.
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
53
APPENDIX
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
U n i v e r s i t y  of  N e w  H a m p s h i r e
January 11, 2006 
Clark, Lisa
Microbiology, Rudman Hall 
Durham, NH 03824
IACUC # :  051203
Approval Date; 12/22/2005 
Review Level: B
Project: Dendritic Cell Maturation by Novel TLR2-LRR-Binding Peptides
The Institutional Animal Care and Use Committee (IACUC) reviewed and approved the protocol 
submitted for this study under Category B on Page 4  of the Application for Review of Vertebrate 
Animal Use in Research or Instruction - the study involves either no pain or potentially involves 
momentary, slight pain, discomfort or stress.
Approval is granted for a period of three years from the approval date above. Continued approval 
throughout the three year period is contingent upon completion of annual reports on the use of 
animals. At the end of the three year approval period you may submit a new application and 
request for extension to continue this project. Requests for extension must be filed prior to the 
expiration of the original approval.
Please Note:
1. All cage, pen, or other animal identification records must include your IACUC #  listed above.
2. Use of animats in research and instruction is approved contingent upon participation in the 
UNH Occupational Health Program for persons handling animals. Participation is mandatory 
for all principal investigators and their affiliated personnel, employees of the University and 
students alike. A Medical History Questionnaire accompanies this approval; please copy and 
distribute to all listed project staff who have not completed this form already. Completed 
questionnaires should be sent to Dr. Gladi Porsche, UNH Health Services.






Research Conduct and Compliance Services, Office of Sponsored Research, Service Building, 
51 College Road, Durham, NH 03824-3585 * Fax: 603-862-3564
55
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
